Pre-Clinical Research
Filter News
Found 6,415 articles
-
The rate of incidence of infection by Naegleria fowleri in the U.S. is very, very low. But there’s something about picking up an incurable, brain-eating amoeba by swimming in freshwater lakes and rivers that understandably freaks people out.
-
January 18 Research Roundup: Skin Cancer, Turning Cancer Cells Into Fat Cells, and a Longevity Test
1/18/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Brain plasticity refers to the brain’s ability to change throughout life. When young, the brain is highly plastic, but becomes less so as we age. Too much plasticity can be a problem, but it's necessary for the brain’s ability to repair itself or reorganize itself after injury or when learning ne...
-
A study published in Clinical Chemistry earlier this month has linked sperm with more DNA damage to repeated miscarriages. Recurring miscarriages, defined as three or more consecutive miscarriages before 20 weeks of pregnancy, occur in 1-2 percent of couples.
-
The researchers identified a group of centyrins that blocked the action of five toxins generated by Staphylococcus aureus, the bacteria that causes Staph infections.
-
After conducting a routine research-and-development review, Pfizer is easing away from preclinical biosimilar development. The bottom line is the company is ending five preclinical programs in its biosimilar area and cutting 150 positions.
-
Your Feedback Matters! Topics in 2019
1/15/2019
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about. -
MDA Awards Venture Philanthropy Grant to AcuraStem to Develop Novel Treatment for ALS
1/15/2019
The Muscular Dystrophy Association has awarded an MDA Venture Philanthropy (MVP) grant totaling $300,000 over two years to AcuraStem Incorporated to support preclinical development of a novel small molecule therapeutic for amyotrophic lateral sclerosis (ALS).
-
Inovio's dMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies
1/15/2019
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the successful development of optimized DNA-encoded monoclonal antibodies (dMAbs™) targeting the immune checkpoint molecule PD-1.
-
Artificial intelligence technology has an established home in drug design for many developers. Now, researchers are seeing it as a potential tool in driving therapeutic choices in the treatment of ovarian cancer.
-
January 11 Research Roundup: Inhalable mRNA, CRISPR and Muscular Dystrophy, Do-It-Yourself DNA De...
1/11/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Amryt Pharma plc: Positive results for novel non-viral gene therapy AP103
1/8/2019
Amryt, a revenue generating orphan drug company focused on acquiring, developing and commercialising products that help improve the lives of patients where there is a high unmet medical need, today announces positive results from two pre-clinical studies which support the development of its novel non-viral gene therapy, AP103, as a potentially disease-modifying therapy for patients with Recessive Dystrophic Epidermolysis Bullosa ("RDEB"), a subset of Epidermolysis Bullosa (“EB”).
-
Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent
1/8/2019
Company filed patent application for the utilization of Namodenoson as an anti-obesity drug
-
January 4 Research Roundup: DNA Origami, Cannabis Potency, Immune System Fountain of Youth and More
1/4/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Action
1/3/2019
Preclinical research demonstrated rapastinel positively modulates the NMDA receptor
-
Researchers with the Francis Crick Institute and the Institute of Cancer Research recently published research suggesting that a new class of drugs that is helpful in treating breast cancers could help treat some of the hardest-to-treat lung cancers.
-
December 28 Research Roundup: Super Leukemia Drug, Synthetic Antibiotics, How Marijuana Changes t...
12/28/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them, from Northwestern, UC Davis, Cornell, Duke, and others. -
Gossamer Bio, headquartered in San Diego, announced plans for its initial public offering (IPO) just before Christmas.
-
December 21 Research Roundup: HIV Vaccine, Super-Accurate Cervical Cancer Test, Molecular Mechani...
12/21/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
12/21/2018
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx).